Patents by Inventor Courtney A. Cullis

Courtney A. Cullis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sting modulator compounds, and methods of making and using
    Patent number: 12054512
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: August 6, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
    Publication number: 20240209017
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 2, 2022
    Publication date: June 27, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
  • Sting modulator compounds, and methods of making and using
    Patent number: 11542293
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 3, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220411404
    Abstract: The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: May 10, 2022
    Publication date: December 29, 2022
    Inventors: David A. Scott, David Heppner, Thomas Gero, Courtney A. Cullis, Ciric To, Shih-Chung Huang, Yongbo Hu, Steve Stroud, Tyler Beyett, Michael Eck, Nathanael S. Gray
  • ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220378757
    Abstract: The disclosure relates to a compound of Formula (I), which acts as an allosteric inhibitor of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compound; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 1, 2022
    Inventors: Courtney A. Cullis, Krista E. Gipson, Yongbo Hu, Shih-Chung Huang, Nathanael S. Gray, David A. Scott, Thomas Gero, David Heppner, Tyler Beyett, Ciric To, Michael Eck
  • STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
    Publication number: 20210171565
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 10, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
  • Heteroaryls and uses thereof
    Patent number: 10538533
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Heteroaryls and uses thereof
    Patent number: 10202373
    Abstract: The present invention provides a compound of formula I: wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: February 12, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, He Xu, Yingchun Ye
  • HETEROARYLS AND USES THEREOF
    Publication number: 20180118762
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 3, 2018
    Inventors: Indu T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CULLIS, Natalie D'AMORE, Paul E. FLEMING, Kenneth M. GIGSTAD, Krista E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen G. STROUD, Tricia J. VOS, Tzu-Tshin WONG, He XU, Tianlin XU, Yingchun YE
  • Heteroaryls and uses thereof
    Patent number: 9802960
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: October 31, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Heteroaryls and uses thereof
    Patent number: 9751854
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 5, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • HETEROARYLS AND USES THEREOF
    Publication number: 20170073326
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: November 9, 2016
    Publication date: March 16, 2017
    Inventors: Indu T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CULLIS, Natalie D'AMORE, Paul E. FLEMING, Kenneth M. GIGSTAD, Krista E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen G. STROUD, Tricia J. VOS, Tzu-Tshin WONG, He XU, Tianlin XU, Yingchun YE
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20170050935
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 23, 2017
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20160039761
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 11, 2016
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • HETEROARYLS AND USES THEREOF
    Publication number: 20150225422
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: January 13, 2015
    Publication date: August 13, 2015
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20150183753
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 2, 2015
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 8901136
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 2, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mitzutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Heteroaryls and uses thereof
    Patent number: 8859768
    Abstract: This invention provides compounds of formula IA or IB: wherein HY, R1, R2, and G1, are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: October 14, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Courtney A. Cullis, Krista E. Granger, Jianping Guo, Masaaki Hirose, Gang Li, Miho Mizutani, Tricia J. Vos
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20140303193
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 9, 2014
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20130345242
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 26, 2013
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead